title: Pathologic fibrinolysis as a cause of clinical bleeding.
authors.affiliation: Department of Medicine, University of Vermont, Burlington.
authors.forename: D C
authors.initials: DC
authors.lastname: Stump
authors.forename: F B
authors.initials: FB
authors.lastname: Taylor
authors.forename: M E
authors.initials: ME
authors.lastname: Nesheim
authors.forename: A R
authors.initials: AR
authors.lastname: Giles
authors.forename: W H
authors.initials: WH
authors.lastname: Dzik
authors.forename: E G
authors.initials: EG
authors.lastname: Bovill
mesh_terms: D000933:Antifibrinolytic Agents / Q000627:therapeutic use; D001780:Blood Coagulation Tests; D004211:Disseminated Intravascular Coagulation / Q000097:blood; D004730:Endothelium, Vascular / Q000293:injuries; D005342:Fibrinolysis / Q000502:physiology*; D005343:Fibrinolytic Agents / Q000009:adverse effects; D006470:Hemorrhage / Q000097:blood / Q000209:etiology*; D006474:Hemorrhagic Disorders / Q000188:drug therapy / Q000235:genetics; D006487:Hemostasis; D006801:Humans; D007938:Leukemia / Q000097:blood; D016031:Liver Transplantation / Q000502:physiology; D010960:Plasminogen Activators / Q000502:physiology; D015849:Plasminogen Inactivators / Q000378:metabolism; D010974:Platelet Aggregation; D000979:alpha-2-Antiplasmin / Q000172:deficiency
chemical_list: D000933:Antifibrinolytic Agents; D005343:Fibrinolytic Agents; D015849:Plasminogen Inactivators; D000979:alpha-2-Antiplasmin; D010960:Plasminogen Activators